Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by First Light Asset Management LLC

First Light Asset Management LLC cut its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 21.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 398,855 shares of the company's stock after selling 107,367 shares during the period. Structure Therapeutics comprises 1.0% of First Light Asset Management LLC's portfolio, making the stock its 26th biggest position. First Light Asset Management LLC owned 0.70% of Structure Therapeutics worth $10,817,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in GPCR. Marshall Wace LLP raised its holdings in shares of Structure Therapeutics by 339.6% in the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock valued at $15,817,000 after purchasing an additional 450,531 shares in the last quarter. Foresite Capital Management VI LLC purchased a new stake in Structure Therapeutics during the fourth quarter worth $11,390,000. Principal Financial Group Inc. boosted its position in Structure Therapeutics by 230.0% during the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company's stock valued at $23,936,000 after acquiring an additional 380,115 shares in the last quarter. Handelsbanken Fonder AB purchased a new position in shares of Structure Therapeutics in the 4th quarter valued at $4,475,000. Finally, CCG Wealth Management LLC purchased a new stake in shares of Structure Therapeutics during the 4th quarter worth $4,068,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GPCR. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research report on Tuesday, April 22nd. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target on the stock. Finally, William Blair started coverage on Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating for the company. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $81.29.

Structure Therapeutics Price Performance

Structure Therapeutics stock traded up $0.33 during trading hours on Thursday, hitting $27.33. 657,602 shares of the stock traded hands, compared to its average volume of 920,381. The firm's 50 day moving average price is $20.28 and its 200-day moving average price is $27.59. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -36.93 and a beta of -1.35. Structure Therapeutics Inc. has a 1 year low of $13.22 and a 1 year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Research analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.